Nutra Pharma Begins Drug Registration Process In Central America For Its Nyloxin Pain Reliever

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that it has begun the drug registration process in Panama for its Nyloxin pain reliever.


"As an important international business center, Panama offers us an opportunity to introduce our Nyloxin pain reliever in Central America," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "We plan to move forward with this drug registration process in conjunction with finalizing our relationship with a prospective local distribution partner that has the resources and capabilities to successfully market and distribute Nyloxin throughout the country," he concluded.


Nyloxin, which was first introduced in November 2009 as a treatment for chronic pain, is currently available in the United States as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.


In the beginning of June, Nutra Pharma announced its partnership with the healthcare products distributor Henry Schein for distribution of its Nyloxin-branded pain relievers in the United States. Henry Schein, which ranks #339 on the Fortune 500 list, is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners.


Additionally, the Company recently selected Grupo Farmac?©utico de Tijuana (GFT) as its exclusive distributor for Nyloxin in Mexico. GFT specializes in the distribution of pharmaceutical products to large, national retailers and to over 3,000 pharmacies throughout Mexico.


Source:

Nutra Pharma Corp.